Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Cash-to-Debt : 0.89 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Jiangsu Aidea Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Jiangsu Aidea Pharmaceutical Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.89.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Jiangsu Aidea Pharmaceutical Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

SHSE:688488' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68 Med: 2.11 Max: No Debt
Current: 0.89

During the past 8 years, Jiangsu Aidea Pharmaceutical Co's highest Cash to Debt Ratio was No Debt. The lowest was 0.68. And the median was 2.11.

SHSE:688488's Cash-to-Debt is ranked worse than
78.24% of 1526 companies
in the Biotechnology industry
Industry Median: 6.315 vs SHSE:688488: 0.89

Jiangsu Aidea Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Jiangsu Aidea Pharmaceutical Co Cash-to-Debt Chart

Jiangsu Aidea Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.98

2,088.23

108.35

2.33

1.07

Jiangsu Aidea Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															1.89	1.32	1.29	1.07	0.89

Competitive Comparison of Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt

For the Biotechnology subindustry, Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt falls into.

Jiangsu Aidea Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Jiangsu Aidea Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	441.105	/	(339.405	+	72.895)
	=	1.07

Jiangsu Aidea Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	402.338	/	(439.058	+	13.369)
	=	0.89

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Jiangsu Aidea Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Jiangsu Aidea Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Aidea Pharmaceutical Co Ltd (SHSE:688488) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 2 Liuzhuang Road, Hanjiang District, Jiangsu Province, Yangzhou, CHN, 225008

Website

http://www.aidea.com.cn

Jiangsu Aidea Pharmaceutical Co Ltd produces and sells human-derived protein products, and also develops some generic drug businesses and distributes Abbott's HIV diagnostic equipment and reagents. The company focuses on development of new chemical entities of anti-tumor, anti-virus and cardiovascular areas, among which two NCE drugs for the treatment of Cancer and AIDS have been approved.

Executives

Yuan Yu	Core technical personnel
Fu He Liang	Director, core technical staff
Su Gu Fang	Core technical personnel
Zhang Ji Bing	Core technical personnel
Wang Jun	Directors, senior managers
Wang Guang Rong	Directors, senior managers
Yu Ke	Directors, senior managers

Jiangsu Aidea Pharmaceutical Co (SHSE:688488) Headlines

No Headlines